NEW YORK, Sept. 26, 2022 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, is reminding investors that class action lawsuits can be filed on behalf of shareholders of Kiromic BioPharma, Inc. KRBPLifeStance Health Group, Inc. LFSTMINISO Group Holding Limited MNSOand Co-Diagnostics, Inc. CODX. Shareholders have until the deadlines below to petition the court to appear as lead plaintiffs. For more information on each case, see the link provided.
Kiromic BioPharma, Inc. KRBP
Collection Period: June 25, 2021 – August 13, 2021 or subject to the Company’s IPO on July 2, 2021
Lead Plaintiff Deadline: October 4, 2022
The complaint alleges that the offer documents did not disclose that the FDA had imposed a clinical lockdown prior to filing the registration statement and prospectus, and that they in fact included statements indicating that this was not the case. Given that the Offering closed on July 2, 2021, more than thirty (30) days after the Company submitted IND applications for its two immunotherapy product candidates, investors have been assured that no clinical lockdown has been issued and clinical trials would begin. However, the Company had received communications from the FDA on June 16 and June 17, 2021 informing it that the FDA is placing the IND applications for its two candidate products on clinical hold. The offering documents did not disclose this information, instead stating that clinical testing is expected to resume in the third quarter of 2021. Clinical testing did not continue in the third quarter of 2021, nor was the FDA likely to issue a clinical lockdown.
For more information on the Kiromic class action go to: https://bespc.com/cases/KRBP
LifeStance Health Group, Inc. LFST
Class Period: As per the Company’s IPO on June 11, 2021
Lead Plaintiff Deadline: October 11, 2022
On or about June 11, 2021, LifeStance completed its IPO and issued 46 million shares at $18 per share.
On August 11th…
Read full story here https://www.benzinga.com/pressreleases/22/09/g29023700/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-kirom